🔍

IOLCP - IOL Chemicals

📊 NSE: IOLCP 🏢 Pharmaceuticals - Indian - Bulk Drugs & Formln 📅 Last Updated: 12/14/2025 8:25

📢 Recent Corporate Announcements

IOLCP Receives EDQM CEP Certificate for Metformin Hydrochloride Process-II

🟢 POSITIVE ⭐ 7/10

REGULATORY 📅 06 Mar 2026, 03:52 PM

IOL Chemicals and Pharmaceuticals Limited (IOLCP) has received a Certificate of Suitability (CEP) from the European Directorate for the Quality of Medicines & Health Care (EDQM) for its API product, Metformin Hydrochloride Process-II. This certification, granted on March 5, 2026, is an addition to the company's existing valid CEP for Metformin Hydrochloride. Metformin is a widely used antidiabetic drug for managing blood sugar levels. This regulatory milestone strengthens the company's ability to supply this critical API to the European market and other regions that recognize EDQM standards.

EDQM granted the CEP for Metformin Hydrochloride Process-II on March 5, 2026
The new certification is in addition to the existing valid CEP already held by the company
Metformin Hydrochloride is a key antidiabetic drug used globally for blood sugar management
The approval enhances IOLCP's regulatory compliance and market access in European territories

💡 Investors should view this as a positive development that reinforces IOLCP's position in the global API market. The additional certification may lead to improved operational flexibility and potential volume growth in the antidiabetic segment.

IOLCP Expands Ethyl Acetate and Acetic Anhydride Capacities via Rs 9.71 Cr Capex

🟢 POSITIVE ⭐ 7/10

EXPANSION 📅 02 Mar 2026, 06:56 PM

IOL Chemicals and Pharmaceuticals Limited has successfully completed the expansion of its manufacturing facilities for Ethyl Acetate and Acetic Anhydride as of March 2, 2026. The Ethyl Acetate capacity has been increased by 20,000 MTPA to reach 1,20,000 MTPA, while Acetic Anhydride capacity grew by 7,000 MTPA to 32,000 MTPA. The total project cost of Rs 9.71 crore was entirely funded through internal accruals, indicating a healthy balance sheet. This expansion is strategically timed as existing facilities were operating at 90-100% utilization.

Ethyl Acetate capacity increased from 1,00,000 MTPA to 1,20,000 MTPA (20% increase)
Acetic Anhydride capacity enhanced from 25,000 MTPA to 32,000 MTPA (28% increase)
Total capital expenditure of Rs 9.71 crore funded through internal accruals
Expansion completed on March 2, 2026, to address high utilization rates and market demand
Aims to improve margin realization through optimum operating leverage

💡 Investors should view this as a positive growth signal as the company is expanding capacity in segments where it already has high utilization. The use of internal accruals for capex further strengthens the investment case by avoiding additional debt.

IOLCP Q3 FY26 Revenue Up 11% to ₹580 Cr; EBITDA Grows 23% with 10.7% Margin

🟢 POSITIVE ⭐ 8/10

EARNINGS 📅 18 Feb 2026, 02:03 PM

IOL Chemicals and Pharmaceuticals reported a resilient Q3 FY26 with revenue growing 10.9% YoY to ₹580 crores and EBITDA rising 22.8% to ₹62.6 crores. The company's diversification strategy is yielding results, with non-ibuprofen APIs now contributing ₹128 crores to the pharmaceutical segment. Despite persistent high fuel costs in Punjab, management expects a 1-2% margin improvement in Q4 FY26. The board declared a 50% interim dividend, and the company maintains a positive growth guidance of 10-15% for FY27.

Revenue from operations increased 10.9% YoY to ₹580 crores, while EBITDA grew 22.8% to ₹62.6 crores.
Non-ibuprofen API portfolio contributed ₹128 crores, reflecting successful diversification away from core ibuprofen products.
Capacity utilization remains robust with Ibuprofen at 90-95% and the Chemicals division at nearly 100%.
Management guided for 10-15% top-line and 15-20% bottom-line growth in FY27, supported by ₹150-200 crore annual capex.
Reported a non-recurring exceptional item of ₹11.2 crores pertaining to new labor law provisions.

💡 Investors should focus on the improving product mix and the ramp-up in paracetamol capacity as key growth drivers. The stock remains a solid play on API diversification and backward integration efficiencies.

IOLCP Discloses Audio Recording Link for Q3 & M9 FY26 Earnings Call

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 12 Feb 2026, 06:03 PM

IOL Chemicals and Pharmaceuticals Limited has released the audio recording of its investor call held on February 12, 2026. The call focused on the company's financial performance for the third quarter and nine months ended December 31, 2025 (FY26). This disclosure is a standard regulatory requirement under SEBI (LODR) Regulations, 2015, ensuring transparency for all shareholders. Investors can access the recording via the provided link to understand management's commentary on operational performance and future outlook.

Audio recording of the Q3 & M9 FY26 earnings call is now available for public access.
The call was conducted on February 12, 2026, following the release of quarterly financial results.
Compliance update submitted under Regulation 30 of SEBI (LODR) Regulations, 2015.
The recording provides management insights into the company's performance for the nine-month period ending FY26.

💡 Investors should listen to the recording to gain insights into the company's margin trends and management's guidance for the upcoming quarters. No immediate trading action is required based solely on this procedural filing.

IOLCP Declares Rs 1 Interim Dividend; Sets Feb 17 as Record Date for FY 2025-26

🟢 POSITIVE ⭐ 7/10

DIVIDEND 📅 12 Feb 2026, 04:36 PM

IOL Chemicals and Pharmaceuticals Limited (IOLCP) has declared an interim dividend of Rs 1 per equity share, representing 50% of the face value of Rs 2, for the financial year 2025-26. The company has designated February 17, 2026, as the record date to identify eligible shareholders for this payout. Detailed guidelines for Tax Deduction at Source (TDS) have been issued, including a 20% deduction rate for accounts without a valid or linked PAN. Resident individual shareholders are exempt from TDS if their total dividend income from the company does not exceed Rs 10,000 during the fiscal year.

Interim dividend of Rs 1 per share (50% of face value) declared for FY 2025-26
Record date for dividend entitlement is fixed for February 17, 2026
TDS of 20% applicable for shareholders with invalid or non-Aadhaar linked PAN
Exemption from TDS for resident individuals if total dividend is below Rs 10,000
Deadline for submitting tax exemption forms (15G/15H) is February 17, 2026

💡 Investors should ensure their PAN is correctly linked and bank details are updated in their demat accounts before the record date. Eligible shareholders should submit Form 15G/15H through the Alankit Assignments portal by February 17 to avoid unnecessary tax deductions.

IOLCP Q3 FY26 Results: EBITDA Grows 22.8% YoY to ₹62.6 Cr; Revenue Up 10.9%

🟢 POSITIVE ⭐ 8/10

EARNINGS 📅 12 Feb 2026, 12:49 PM

IOL Chemicals and Pharmaceuticals Limited (IOLCP) reported a steady Q3 FY26 performance with revenue growing 10.9% YoY to ₹580.4 Cr. EBITDA margins improved to 10.7% from 9.7% YoY, while PBT before exceptional items surged 39.3% to ₹38.8 Cr. The bottom line was slightly impacted by an exceptional charge of ₹11.2 Cr related to new labour code provisions. The company is successfully diversifying its portfolio, with the non-Ibuprofen segment now contributing significantly to growth.

Revenue from operations increased 10.9% YoY to ₹580.4 Cr in Q3 FY26.
EBITDA grew 22.8% YoY to ₹62.6 Cr with margins expanding by 100 bps to 10.7%.
PBT before exceptional items rose 39.3% YoY to ₹38.8 Cr.
Commenced New Unit 11 for Paracetamol with a significant installed capacity of 10,800 MTPA.
Maintains a very strong financial position with a Debt-to-Equity ratio of 0.07.

💡 Investors should focus on the company's successful transition from an Ibuprofen-heavy player to a diversified API manufacturer. The massive expansion in Paracetamol capacity and low leverage provide a strong foundation for long-term growth.

IOLCP Q3 FY26 Results: PBT Jumps 39.3% YoY to ₹38.8 Cr; Pharma Revenue Up 18%

🟢 POSITIVE ⭐ 8/10

EARNINGS 📅 11 Feb 2026, 06:14 PM

IOL Chemicals and Pharmaceuticals (IOLCP) reported a robust Q3 FY26 performance with revenue growing 10.9% YoY to ₹580.4 crore. Profit Before Tax (before exceptional items) surged by 39.3% YoY to ₹38.8 crore, supported by a 102 bps expansion in EBITDA margins to 10.7%. The growth was largely driven by the Pharmaceuticals segment, which saw an 18% revenue increase and now accounts for 61% of the total revenue mix, up from 57% last year.

Revenue from operations increased 10.9% YoY to ₹580.4 Cr in Q3 FY26.
PBT (before exceptional items) grew 39.3% YoY to ₹38.8 Cr with a margin of 6.6%.
Pharmaceuticals segment EBIT rose 32% YoY to ₹34.5 Cr, driven by non-Ibuprofen APIs.
Chemicals segment EBIT grew 37% YoY to ₹6.5 Cr despite flat revenue growth.
9M FY26 EBITDA stands at ₹196.1 Cr, up 24.8% compared to the previous year.

💡 Investors should note the positive shift in product mix towards the higher-margin Pharmaceutical segment and the successful diversification into non-Ibuprofen APIs. The consistent margin expansion over the nine-month period suggests strong operational efficiency and resilience against global headwinds.

IOLCP Reports Q3 Revenue Growth of 11% YoY and Declares ₹1 Interim Dividend

🟢 POSITIVE ⭐ 8/10

EARNINGS 📅 11 Feb 2026, 02:51 PM

IOL Chemicals and Pharmaceuticals (IOLCP) reported a 10.9% YoY increase in Q3 FY26 revenue to ₹580.39 crore. The company declared an interim dividend of ₹1 per share (50% of face value) with a record date of February 17, 2026. Net profit for the quarter remained flat at ₹20.58 crore, primarily due to an exceptional item of ₹11.21 crore. However, the nine-month performance remains strong with PAT rising 21.8% to ₹84.54 crore compared to the previous year.

Declared an interim dividend of ₹1 per equity share (50% of FV ₹2) with Record Date as Feb 17, 2026.
Q3 Revenue from operations increased by 10.9% YoY to ₹580.39 crore from ₹523.30 crore.
Nine-month (9M FY26) Net Profit grew by 21.8% to ₹84.54 crore from ₹69.38 crore YoY.
Pharmaceutical segment revenue grew to ₹356.05 crore in Q3, up from ₹300.58 crore in the same quarter last year.
Reported an exceptional item of ₹11.21 crore during the quarter, which impacted the quarterly profit before tax.

💡 Investors should note the record date of February 17 for dividend eligibility. The steady revenue growth in the pharmaceutical segment is a positive indicator for long-term growth despite the quarterly impact of exceptional items.

IOLCP Q3 Revenue Up 11% YoY to ₹580 Cr; Declares ₹1 Interim Dividend

🔵 WATCH ⭐ 7/10

EARNINGS 📅 11 Feb 2026, 02:47 PM

IOL Chemicals and Pharmaceuticals reported a standalone revenue growth of 11% YoY to ₹580.39 crore for the quarter ended December 2025. While the Pharmaceutical segment saw robust growth in both revenue and profit, the overall Net Profit remained flat at ₹20.58 crore due to an exceptional charge of ₹11.21 crore. On a nine-month basis, the company showed improved performance with PAT rising to ₹84.54 crore from ₹69.38 crore. Additionally, the board rewarded shareholders with an interim dividend of ₹1 per share.

Revenue from operations increased 11% YoY to ₹580.39 crore in Q3 FY26.
Pharmaceutical segment revenue grew 18.5% YoY to ₹356.05 crore from ₹300.58 crore.
Net Profit for Q3 was ₹20.58 crore, impacted by an exceptional item of ₹11.21 crore.
Interim dividend of ₹1 per share (50%) declared with record date of Feb 17, 2026.
9M FY26 Revenue reached ₹1,699.61 crore compared to ₹1,551.43 crore in the previous year.

💡 Investors should monitor the nature of the exceptional item and the margin recovery in the chemical segment. The strong performance in the pharmaceutical division is a positive long-term indicator.

IOL Chemicals Schedules Q3 & 9M FY26 Earnings Conference Call for February 12, 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 04 Feb 2026, 04:59 PM

IOL Chemicals and Pharmaceuticals Limited (IOLCP) has announced its earnings conference call to discuss the financial results for the third quarter and nine months ended December 31, 2025. The call is scheduled for Thursday, February 12, 2026, at 3:00 PM IST. Senior management, including the CFO and Director Works, will be present to interact with analysts and institutional investors. This is a standard regulatory filing to inform stakeholders about the upcoming performance review session.

Conference call scheduled for February 12, 2026, at 3:00 PM IST.
Agenda focuses on financial performance for Q3 and 9M FY26 ended December 31, 2025.
Management participants include CFO Pardeep Kumar Khanna and Director Works Kushal Kumar Rana.
International access numbers provided for investors in USA, UK, Singapore, and Hong Kong.

💡 Investors should monitor the call for management commentary on Ibuprofen pricing trends and the performance of the specialty chemicals segment. No immediate action is required as this is a routine scheduling announcement.

IOLCP to Strike Off Non-Operational Subsidiary IOL Life Sciences Limited

🟡 NEUTRAL ⭐ 3/10

REGULATORY 📅 27 Jan 2026, 06:18 PM

IOL Chemicals and Pharmaceuticals Limited (IOLCP) has filed an application with the Registrar of Companies to strike off its wholly owned subsidiary, IOL Life Sciences Limited. The subsidiary is currently non-operational, having reported zero revenue and zero percentage contribution to the parent company's turnover for the financial year ending March 31, 2025. The net worth of the subsidiary is negligible at approximately Rs. 6.38 lakh. This move is a routine administrative action to dissolve an inactive entity and will have no material impact on the company's consolidated financials.

Application filed on January 27, 2026, to strike off IOL Life Sciences Limited from the register of companies.
The subsidiary contributed 0% to the company's total revenue in the last financial year.
Net worth of the subsidiary as of March 31, 2025, stood at a minor Rs. 6,38,838.
The strike-off process is subject to necessary approvals from the Ministry of Corporate Affairs and RoC.

💡 No action is required from investors as this is a routine corporate cleanup of a non-performing, zero-revenue subsidiary. It does not affect the core business operations or profitability of IOLCP.

IOL Chemicals Submits SEBI Regulation 74(5) Compliance Certificate for Q3 FY26

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 08 Jan 2026, 05:28 PM

IOL Chemicals and Pharmaceuticals Limited has submitted its compliance certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended December 31, 2025. The certificate, issued by Registrar Alankit Assignments Limited, confirms that physical share certificates received for dematerialization have been processed and cancelled. This filing ensures that the company's shareholding records are accurately updated with the depositories. Such filings are standard procedural requirements for all listed entities in India and do not impact business fundamentals.

Compliance with Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018.
Covers the quarterly period ending December 31, 2025.
Confirmation from Registrar Alankit Assignments Limited regarding dematerialization requests.
Verification that physical certificates were mutilated, cancelled, and depository names substituted in records.
Submission made to both NSE and BSE within the regulatory time limits.

💡 No action is required as this is a routine administrative filing. Investors should focus on the company's upcoming quarterly financial results for performance assessment.

IOLCP Announces Trading Window Closure from January 1, 2026 for Q3 Results

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 29 Dec 2025, 03:11 PM

IOL Chemicals and Pharmaceuticals Limited (IOLCP) has announced the closure of its trading window starting January 1, 2026, in compliance with SEBI Insider Trading regulations. The closure is ahead of the declaration of the company's unaudited financial results for the quarter and nine months ending December 31, 2025. The window will remain closed for all designated persons and their immediate relatives until 48 hours after the results are made public. The specific date for the board meeting to approve these results will be communicated at a later date.

Trading window closure effective from January 1, 2026
Closure relates to the financial results for the quarter and nine months ended December 31, 2025
Window to reopen 48 hours after the official announcement of financial results
Compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015

💡 This is a routine regulatory announcement and does not impact the company's fundamentals. Investors should monitor for the upcoming board meeting date to assess the Q3 FY26 financial performance.

IOLCP gets EDQM CEP Certificate for MINOXIDIL

🟢 POSITIVE ⭐ 6/10

REGULATORY 📅 05 Dec 2025, 03:52 PM

IOL Chemicals and Pharmaceuticals Limited has received a Certificate of Suitability (CEP) from the European Directorate for the Quality of Medicines & Health Care (EDQM) for its API product "MINOXIDIL" on December 4th, 2025. Minoxidil is used for treating hereditary hair loss. This certification indicates that IOLCP's Minoxidil meets European quality standards, potentially opening up new markets and increasing export opportunities. This regulatory approval can positively impact the company's revenue from API sales.

EDQM granted CEP Certificate for MINOXIDIL on December 4th, 2025
MINOXIDIL is used as a topical treatment for hereditary hair loss
Certificate issued by the European Directorate for the Quality of Medicines & Health Care (EDQM)

💡 Investors should monitor IOLCP's sales and revenue growth in the coming quarters to assess the financial impact of this certification. Keep an eye on further regulatory approvals in other geographies.

View All IOLCP Announcements on Live Market Tracking →

💰 Financial Performance

Revenue Growth by Segment

In Q2 FY26, total revenue from operations reached INR 567.5 Cr, reflecting a 7.9% YoY growth. Historically, in FY24, the Pharma segment remained stable with a marginal 0.3% increase, while the Chemical segment saw a 9% decline due to pricing pressures. The company is currently targeting a 10-15% annual revenue growth across segments.

Geographic Revenue Split

The company is strategically shifting from domestic to regulated markets (Europe and US) to improve price realization. It aims to increase its export revenue share to approximately 40% of total sales, supported by 15 DMFs and 20 CEPs filed for regulated markets.

Profitability Margins

Profitability showed significant YoY improvement in Q2 FY26 with PAT margins rising to 5.2% from 3.6% (INR 30 Cr, up 56.7% YoY). However, margins saw a temporary sequential dip due to elevated fuel costs (Punjab floods). FY24 PAT margin stood at 6.31% (INR 135.42 Cr) but moderated to 4.8% (INR 101 Cr) in FY25.

EBITDA Margin

EBITDA for Q2 FY26 was INR 64 Cr, a 33.3% YoY increase, with margins expanding by 212 basis points to 11.1%. The company targets an EBITDA margin of 13-14% in the near term, expecting a 1-2% annual improvement through better product mix and operational leverage.

Capital Expenditure

IOLCP plans to fund its entire capex for the next three years through internal accruals. Recent investments are focused on automation, infrastructure upgrades, and scaling the differentiated API pipeline to support a 10-15% growth trajectory.

Credit Rating & Borrowing

The company maintains a strong credit profile with CARE A+ (Stable) for long-term and CARE A1+ for short-term facilities. Overall gearing is low at 0.24x as of March 31, 2025, with an interest coverage ratio of 14.27x.

⚙️ Operational Drivers

Raw Materials

Key raw materials include Acetic Acid (primary for Ethyl Acetate), Iso-Butyl Benzene (IBB), and various chemical intermediates for APIs like Metformin and Paracetamol. Raw materials are a major cost driver, with Ethyl Acetate and Ibuprofen accounting for 72% of FY24 revenue.

Import Sources

The company procures the majority of its raw materials for the chemical segment from China. API raw materials are primarily sourced from the domestic Indian market.

Capacity Expansion

Total blended manufacturing capacity reached 1,80,222 MTPA as of March 31, 2025, up from 1,72,962 MTPA in FY24. Paracetamol capacity utilization is currently 55-56%, with a target to reach 65% by next year.

Raw Material Costs

Raw material costs are volatile; for instance, Ethyl Acetate margins are highly sensitive to Acetic Acid price fluctuations. The company passes on cost increases to customers with a lag of approximately two months due to inventory processing cycles.

Manufacturing Efficiency

Efficiency is driven by integrated operations where chemical segment products serve as intermediates for the API segment, reducing overall cost structures and improving operating leverage.

📈 Strategic Growth

Expected Growth Rate

10-15%

Growth Strategy

Growth will be achieved by shifting the customer base from domestic to regulated markets (Europe/US) to capture higher margins, increasing Paracetamol capacity utilization to 65%, and expanding the API portfolio (Metformin, Clopidogrel, Pantoprazole). The company is also securing clearances for new land for future industrial expansion.

Products & Services

Major products include Ibuprofen (36% of sales), Ethyl Acetate (36% of sales), Metformin, Paracetamol, Clopidogrel, Fenofibrate, Pantoprazole, Acetyl Chloride, and Iso-Butyl Benzene.

Brand Portfolio

IOL Chemicals and Pharmaceuticals Limited (IOLCP).

New Products/Services

The company is scaling its 'differentiated API pipeline' and has recently introduced Metformin, Clopidogrel, and Fenofibrate to reduce product concentration risk.

Market Expansion

Targeting regulated markets with 18 approved CEPs and 15 DMFs. The company is specifically looking to grow its presence in the US and Europe to achieve a 40% export revenue share.

Market Share & Ranking

IOLCP is a well-established market leader in Ibuprofen globally, with an installed capacity of 12,000 MTPA.

🌍 External Factors

Industry Trends

The industry is shifting toward high-quality, regulated market manufacturing. IOLCP is positioning itself by moving away from the domestic-heavy mix to a 40% export-oriented model to capture stable demand and better pricing.

Competitive Landscape

The company faces competition from domestic and Chinese manufacturers in the API and Ethyl Acetate markets, leading to selling price pressure as seen in Q1 FY25.

Competitive Moat

The moat is built on backward integration and cost leadership in Ibuprofen. By manufacturing its own key starting materials (KSMs) like IBB, IOLCP maintains a favorable cost structure that is difficult for non-integrated competitors to match.

Macro Economic Sensitivity

The business is sensitive to global pharmaceutical demand and industrial chemical cycles. Inflation in fuel and raw material costs directly impacts the 11.1% EBITDA margin.

Consumer Behavior

Stable and growing global demand for essential APIs like Ibuprofen and Paracetamol supports long-term volume recovery.

Geopolitical Risks

Heavy reliance on China for raw materials (Acetic Acid) exposes the company to trade disruptions and geopolitical tensions between India and China.

⚖️ Regulatory & Governance

Industry Regulations

Operations are subject to USFDA standards (Ibuprofen facility approved in FY20). Notably, IOLCP's products are not covered under the Drug Price Control Order (DPCO), allowing for more flexible pricing.

Environmental Compliance

The company is in the process of securing environmental clearances for new land. It has received approvals from pollution control boards and focuses on minimizing adverse impacts on health and safety.

Taxation Policy Impact

The effective tax rate resulted in a PAT of INR 30 Cr from a PBT level in Q2 FY26, reflecting standard corporate tax applications.

Legal Contingencies

As of March 31, 2025, no significant or material orders were passed by regulators, courts, or tribunals impacting the company's status as a going concern. No proceedings are admitted under the Insolvency and Bankruptcy Code.

⚠️ Risk Analysis

Key Uncertainties

The primary uncertainty is the volatility of raw material prices from China, which can impact margins by 1-2% annually. Regulatory delays in new product approvals could also impact the 10-15% growth target.